Recently, the CDC rolled out a new COVID vaccine for individuals who have yet to receive the shot in the United States.
At this juncture in time, approximately 77 percent of the United States population has been fully vaccinated against COVID-19.
In the United States, “fully vaccinated” entails having at least two shots of the Pfizer or Moderna vaccine, or one shot of the J&J vaccine.
The percentage of the population that remains unvaccinated is believed to be leery about the new technology, especially mRNA, underlying the shots first cleared by the FDA. The CDC is hopeful that the introduction of Novavax, Inc., which was manufactured in India, will persuade Americans who haven’t yet been vaccinated to choose to do so.
According to Rochelle Walensky, who serves as the CDC director, the decision to approve and promote Novavax expands “the options available” to American adults for vaccines.
“If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, [such as Pfizer and Moderna], now is the time to join the millions of Americans who have been vaccinated,” Walensky announced.
Walensky’s recommendation emerges after the CDC’s Advisory Committee on Immunization Practices (ACIP) supported Novavax in a unanimous manner, just a week after the United States Food and Drug Administration (FDA) authorized the vaccination as a two-dose series.
Approximately 3.2 million Novavax vaccine doses have been secured by the United States government.
In contrast to other vaccines, Novavax features a protein-based formula, an older formula that has been used for several decades to combat various illnesses, including influenza and Hepatitis B.
Demand for the vaccine has generally been much higher in Europe, where at least 13 million Novavax shots have been administered.
In contrast, approximately 250,000 shots have been administered in the United States.
The results of a recent clinical trial, which featured 30,000 participants, reveal that Novavax is 90 percent effective at preventing illness from COVID.
In addition, the vaccine also demonstrates a strong response to different variants circulating throughout the world, including the omicron subvariants BA.4 and BA.5.